The clinical, diagnostic, therapeutic, and prognostic characteristics of brain metastases in prostate cancer: a systematic review
S Mirmoeeni, A Azari Jafari, M Shah, F Salemi… - Prostate …, 2022 - Wiley Online Library
Aim. Prostate cancer (PCa) is the second most common nonskin malignancy and the second
most common cause of cancer‐related deaths in men. The most common site of metastasis …
most common cause of cancer‐related deaths in men. The most common site of metastasis …
Management of patients with advanced prostate cancer: Report of the Taiwan Advanced Prostate Cancer Consensus Conference 2022
SC Hung, YS Lin, YH Chang, YS Pu, TTL Wu… - Urological …, 2024 - journals.lww.com
The landscape for advanced prostate cancer has significantly evolved over the past decade.
However, there remains a notable lack of robust evidence across various facets of clinical …
However, there remains a notable lack of robust evidence across various facets of clinical …
[HTML][HTML] Components of the Endosome-Lysosome Vesicular Machinery as Drivers of the Metastatic Cascade in Prostate Cancer
Prostate cancer remains a significant global health concern, with over 1.4 million new cases
diagnosed and more than 330,000 deaths each year. The primary clinical challenge that …
diagnosed and more than 330,000 deaths each year. The primary clinical challenge that …
Efficacy of new therapies for relapse after docetaxel treatment of bone metastatic castration-resistant prostate cancer in clinical practice
A Mizokami, K Nishimoto, H Matsuyama… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: To assess the efficacy of novel therapeutic agents, such as androgen
receptor axis-targeted agents (ARATs) and cabazitaxel, for relapse of metastatic castration …
receptor axis-targeted agents (ARATs) and cabazitaxel, for relapse of metastatic castration …
Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
Introduction In recent years, enzalutamide and abiraterone have been widely used as
treatments for metastatic castration-resistant prostate cancer (mCRPC). However, the cost …
treatments for metastatic castration-resistant prostate cancer (mCRPC). However, the cost …
Efficacy of novel hormone agents in the treatment of metastatic castration-resistant prostate cancer: A real-world retrospective study
JR Li, S Wang, C Chen, C Yang, K Lu… - Anticancer …, 2022 - ar.iiarjournals.org
Abstract Background/Aim: Novel hormone agents (NHA) have become important tools for
the treatment of advanced prostate cancer. Among them, abiraterone and enzalutamide are …
the treatment of advanced prostate cancer. Among them, abiraterone and enzalutamide are …
Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases
N Wakita, T Hara, K Suzuki, T Terakawa… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Radium-223 therapy has been reported to improve prognosis in patients
with castration-resistant prostate cancer (CRPC) and bone metastases. Occasionally …
with castration-resistant prostate cancer (CRPC) and bone metastases. Occasionally …
[HTML][HTML] Efficacy of Enzalutamide Rechallenge for Metastatic Castration-Resistant Prostate Cancer
H Sawazaki, Y Kitamura, U Madoka… - Asian Pacific Journal …, 2024 - pmc.ncbi.nlm.nih.gov
Objective: There have been several reports on rechallenge with docetaxel, cabazitaxel,
abiraterone acetate, or ethinylestradiol for metastatic castration-resistant prostate cancer …
abiraterone acetate, or ethinylestradiol for metastatic castration-resistant prostate cancer …
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis
T Kamijima, H Yaegashi, A Mizokami… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: This study aimed to evaluate the therapeutic benefit of novel androgen
receptor-targeted agents (ARTAs) in castration-resistant prostate cancer (CRPC) with bone …
receptor-targeted agents (ARTAs) in castration-resistant prostate cancer (CRPC) with bone …
[PDF][PDF] Research Article The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review
S Mirmoeeni, AA Jafari, M Shah, F Salemi, SZ Hashemi… - 2022 - academia.edu
Aim. Prostate cancer (PCa) is the second most common nonskin malignancy and the second
most common cause of cancer• related deaths in men. Te most common site of metastasis in …
most common cause of cancer• related deaths in men. Te most common site of metastasis in …